Introduction {#s1}
============

Probiotic bifidobacteria such as *Bifidobacterium longum* (*B. longum*), *Bifidobacterium breve*, *Bifidobacterium animalis*, and *Bifidobacterium bifidum* are commonly used as starter cultures in the dairy industry e.g., fermented milk, cheese and infant formulas ([@r003]; [@r006]; [@r027]; [@r029]; [@r038]) because of their beneficial effects for human health. The various beneficial effects include the pathogenic species inhibition, diminution of colon cancer risk, immune response for protection effect on their function, regulation of gut microflora ([@r001]; [@r003]; [@r004]; [@r025]).

As lactic acid bacteria (LAB) including *Lactococcus lactis* (*L. lactis*), *Lactobacillus rhamnosus* (*Lb. rhamnosus*), *Streptococcus thermophilus* (*St. thermophilus*), *Lactobacillus lactis* (*Lb. lactis*), *Lactobacillus helveticus* (*Lb. helveticus*), and *Lactobacillus* subsp. *bulgaricus* (*Lb. bulgaricus*), bifidobacteria strains for their growth also use milk protein as a nitrogen source, and their proteolytic system can produce peptides in milk ([@r003]; [@r021]). The proteolytic system of LAB as *St. thermophilus*, *Lb. rhamnosus*, *L. lactis*, *Lb. bulgaricus*, *Lb. helveticus* is composed of 3 steps which contain the cell envelope protease (CEP), a transporter of oligopeptides and small peptides, and the various intracellular peptidases ([@r009]; [@r010]; [@r030]; [@r032]; [@r040]; [@r043]).

The proteolytic system of bifidobacteria is not well known. Some studies have shown that peptidases of the genus *Bifidobacterium* can hydrolyze milk protein directly, including those of *Bifidobacterium animalis* subsp. *lactis* ([@r021]), *Bifidobacterium longum* Bl 536 ([@r008]), and *B. longum* KACC 91563 ([@r003]) generating the biological peptides. Hydrolysis of milk protein by microorganisms during fermentation can generate various peptides, including biologically active peptides, e.g., angiotensin I-converting enzyme (ACE) inhibitory peptides, antioxidant peptides, opiates, antimutagens, immunomodulatory peptides, antimicrobial peptides, or peptides with mineral binding activity. The bioactive peptides produced by the activity of proteases or peptidases of microorganisms are well documented in the literature ([@r024]). The most studied commercial fermented milk products are "Calpis" and "Evolus", including two ACE-inhibitory tripeptides, VPP and IPP generated from β-casein by fermentation with *Lb. helveticus* including *Saccharomyces cerevisiae* for Calpis and *Lb. helveticus* for Evolus have been commercialized ([@r024]; [@r041]; [@r044]).

In the case of bifidobacteria, the antioxidative peptides produced by *B. longum* were reported by [@r003]. Another study showed that the bioactive peptides of *B. longum* Bl 536 presented in *vitro* ACE-inhibitory activity, indicating that these are potential hypotensive peptides ([@r008]); however, the peptides were not identified. Inhibition of ACE activity is regarded as an important component for the treatment of patients with hypertension because ACE leads to an increase in blood pressure by conversion of angiotensin I to angiogestin II or by bradykinin hydrolysis ([@r011]; [@r016]; [@r031]; [@r033]). Recently, some novel ACE-inhibitory peptides, including LVYPFP, were identified in *Bifidobacterium bifidum* ([@r014]). However, no hypotensive peptides have been identified in *B. longum* to date. Thus, we sought to investigate the antihypertensive activity and identify the peptides released from casein (CN) during fermentation of milk by *B. longum* KACC 91563.

Material and Methods {#s2}
====================

Materials {#s2a}
---------

Chemical reagents, including hippuryl-histydil-leucine(HHL), captopril, ACE (2 mU; EC 3.4.15.1, 5.1 U mg^−1^), and lung acetone powder from rabbit were purchased from Sigma Aldrich (USA), and all other chemicals used were of analytical grade.

Preparation and growth of *Bifidobacterium longum* KACC91563 {#s2b}
------------------------------------------------------------

*B. longum* KACC91563 was isolated from infant feces in Korea. Identification of this strain was performed according to previously described methods ([@r003]; [@r015]). After isolation, *B. longum* was grown according to the conditions described by [@r037]. *B. longum* KACC91563 was grown in de Man, Rogosa, and Sharpe (MRS) broth (BD Biosciences, USA) containing cysteine (0.05% final concentration), and the cells (bacteria) were harvested by centrifugation (Beckman Coulter, USA) at 3,200 *g* for 30 min at 4℃. The cells were incubated and stored in reconstituted skim milk (10% w/v) at 80℃.

Milk fermentation {#s2c}
-----------------

To obtain the fermentate fraction, fermentation was performed in skimmed milk for 24 h by inoculation of 1% *B. longum* after preculture at 37℃. The fermentate was retrieved by centrifugation at 3,200 *g* for 15 min at 4℃ when the fermentation was complete. The obtained fractions were separated using an ultrafiltration membrane system (Millipore, USA) with a molecular weight cut-off of 3 kDa.

Measurement of ACE inhibitory activity {#s2d}
--------------------------------------

ACE inhibitory activity was measured using a spectrophotometric assay as previously described ([@r005]) with slight modifications. First, crude ACE was prepared and extracted from 1 g of rabbit lung acetone powder (L0756, Sigma Aldrich) by gentle mixing of 40 mL of 0.1 M sodium borate buffer (pH 8.3) containing 0.3 M NaCl over 24 h. The supernatant containing ACE was obtained by centrifugation a 3,200 *g* for 40 min at 4℃, and was used for ACE inhibitory activity. A 50 μL sample was added to 100 μL of 0.1 M sodium borate buffer (pH 8.3) containing 0.3 M NaCl, and 50 μL of crude ACE was obtained. The reaction mixture was pre-incubated at 37℃ for 5 min. Fifty microliters of 12.5 mM HHL (H-1635, Sigma Aldrich) solubilized in 0.1 M sodium borate buffer (pH 8.3) containing 0.3 M NaCl was added to the reaction mixture and left to stand for 30 min at 37℃ after vortexing. To stop the enzyme reaction, 250 μL of 1 N HCl was added. Next, 1.5 mL of ethyl acetate was added to this reaction mixture and vortexed for 15 s. One milliliter of supernatant was retrieved by centrifugation at 3,000 g for 5 min and evaporated using Concentrator Plus (Eppendorf, Germany) at 60℃ for 30 min. The product was resupended in 1 mL of distilled water and its absorbance was measured at 228 nm using a spectrophotometer (Molecular Devices, USA). All assays were carried out in triplicate and the values represent the average and standard errors. Captopril (C-4042, Sigma Aldrich) was used as a positive control. The ACE inhibitory activity was calculated as follows: ACE inhibition (%) = \[(C − B) − (S − B)\] × 100/(C − B), where S is the absorbance of the ACE, ACE-inhibitory sample, and HHL; B is the absorbance of ACE and sodium borate buffer (pH 8.3) without HHL; and C is the absorbance of ACE, sodium borate buffer (pH 8.3), and HHL.

Identification of peptides by mass spectrometry {#s2e}
-----------------------------------------------

Liquid chromatography-electrospray ionization-quantitative time-of-flight tandem mass spectrometry experiments (LC-ESI-TOF-MS/MS) were performed at the National Instrumentation Center for Environmental Management (NICEM) of Seoul National University in Korea, according to the method described by [@r002].

MS analysis experiments were carried out using an integrated system consisting of an auto-switching nano pump, autosampler (Tempo^TM^ nano LC system; MDS SCIEX, Canada), and a hybrid quadrupole-time-of-flight (TOF) mass spectrometer (QStar Elite; Applied Biosystems, USA) fitted with a fused silica emitter tip (New Objective, USA). For ionization, the nano-electrospray ionization (ESI) was applied. Two μL fractions were injected into the LC-nano ESI-MS/MS system.

Samples were first trapped on a ZORBAX 300SB-C18 trap column (300-μm i.d × 5 mm, 5-μm particle size, 100 pore size, Agilent Technologies, part number 5065-9913) and washed for 6 min with gradient with 98% solvent A and 2% solvent B at a flow rate of 5 μL/min. The solvent A and B consisted in \[water/acetonitrile (98:2, v/v), 0.1% formic acid\] and \[Water/acetonitrile (2:98, v/v), 0.1% formic acid\]. Separation was carried out on a ZORBAX 300SB-C18 capillary column (75-μm i.d × 150 mm, 3.5-μm particle size, 100 pore size, part number 5065-9911) at a flow rate of 300 nL/min with gradient at 2% to 35% solvent B over 30 min, then from 35% to 90% over 10 min, followed by 90% solvent B for 5 min, and finally 5% solvent B for 15 min. Electrospray through a coated silica tip (FS360-20-10-N20-C12, PicoTip emitter, New Objective) was performed at an ion spray voltage of 2,000 eV. Peptides were analyzed automatically using Analyst QS 2.0 software (Applied Biosystems, USA). The range of m/z values was 200-2000.

Results and Discussion {#s3}
======================

Determination of *in vitro* ACE inhibitory activity in low molecular weight fermentate {#s3a}
--------------------------------------------------------------------------------------

Two fractions were prepared to evaluate the ACE inhibitory activity. One was the fraction obtained after *B. longum* KACC9156 fermentation in skimmed milk for 24 h. Fermentates were fractionated at a molecular weight cutoff of 3 kDa using a centrifugal ultrafiltration membrane system. This cutoff value was chosen because [@r014] demonstrated that the \<3 kDa fraction of *B. bifidum* MF 20/5-fermented milk showed higher ACE inhibitory activity than that of the \>3-kDa fraction. Similarly, [@r031] showed that the 50% inhibitory concentration of ACE was higher (5.5 μg/mL) in the \<3 kDa fraction than in the \> 3 kDa fractions of the bovine CN hydrolysate and whole hydrolysate without molecular weight fractionation. Confirming these results, in the present study, the ACE inhibitory activity determined from the fermentate obtained from milk fermentation with *B. longum* was 62.3% ([Table 1](#t001){ref-type="table"}), which was higher than that of the CN hydrolysate (28.3% ACE inhibitory activity) obtained from a 0.1% CN solution in 0.05 M sodium phosphate buffer (pH 7.0) at the same incubation time (data not shown). This ACE inhibitory activity was similar to that reported previously (63.7%) in milk fermented with *B. longum* B1 536 ([@r008]). During fermentation, the casein could be degraded by the protolytic system of *B. longum* which was detected on peptidase activity of their cell surface ([@r003]). However, the cell envelop protease of *B. longum* which is the first step of casein hydrolysis was not found. From this reason, the ACE inhibitory activity in this work could be resulted from the potential cell wall peptidase.

###### ACE-inhibitory activities in the low-molecular-weight fraction (\<3 kDa) of the fermentate obtained after incubation of milk by *Bifidobacterium longum* KACC 91563

                 Control       Fermentate
  -------------- ------------- -------------
  A~228~         0.715±0.027   0.375±0.011
  Activity (%)   0             62.3

All assays were carried out in triplicate.

Using LC-ESI-MS/MS, the further study was proceeded to identify the peptides and to search the antihypertensive peptides generated by fermentation with *B. longum* KACC 9156 in milk.

Peptides generated from milk casein during fermentation by *Bifidobacterium longum* KACC9156 {#s3b}
--------------------------------------------------------------------------------------------

The peptides generated from fermentates were identified by LC-ESI-TOF-MS/MS. As shown in [Table 2](#t002){ref-type="table"}, the peptides in the fermentate were identified to have been generated from CN. The results also indicated that CN was the preferential substrate of *B. longum* in spite of the presence of whey protein in skim milk, similar to a strain of *St. thermophilus* ([@r002]). A total of 28 peptides were generated, corresponding to 11 β-CN, 16 α~s1~-CN, and 1 κ-CN peptide. This observation was slightly different from that reported by [@r003], who identified 33 peptides (19 β-CN, 12 α~s1~-CN, and 2 κ-CN) in bovine CN hydrolysates obtained from a 0.1% CN solution with the same strain of *B. longum*. This difference could be explained by a difference in the accessibility of peptides for hydrolysis by *B. longum* or in a structural difference of milk protein in the different matrices used, i.e., milk versus buffer.

###### Casein-derived peptides identified by liquid chromatography electrospray ionization time-of-flight tandem mass spectrometry in the \<3 kDa fraction of the 24 h fermentates obtained from fermentation of milk by *Bifidobacterium longum* KACC91563

  Names   Peptide sequence              Prec MW     Prec m/z   Theor MW    Theor m/z   z
  ------- ----------------------------- ----------- ---------- ----------- ----------- ---
  β-CN    f1-25, RELEELNVPGEIVE         1623.8091   812.9118   1623.8468   812.9307    2
          f109-125, MPFPKYPVEPFTESQSL   1995.9216   998.9681   1995.9652   998.9899    2
          f193-206, YQEPVLGPVRGPFP      1554.7750   778.3948   1554.8195   778.4170    2
          f193-209, YQEPVLGPVRGPFPIIV   1880.0123   941.0134   1880.0560   941.0353    2
          f194-209, QEPVLGPVRGPFPIIV    1699.9307   850.9726   1699.9662   850.9904    2
          f195-206, EPVLGPVRGPFP        1263.6628   632.8387   1263.6975   632.8561    2
          f195-209, EPVLGPVRGPFPIIV     1588.9012   795.4579   1588.9341   795.4743    2
          f196-209, PVLGPVRGPFPIIV      1459.8593   730.9369   1459.8915   730.9530    2
          f197-209, VLGPVRGPFPIIV       1362.8054   682.4100   1362.8387   682.4266    2
          f198-209, LGPVRGPFPIIV        1263.7390   632.8768   1263.7704   632.8925    2
          f199-209, GPVRGPFPIIV         1150.6611   576.3378   1150.6863   576.3504    2

CN: casein, *m/z* = mass to charge ratio, where *z* = number of positively charged ions.

Nonetheless, the pattern of CN hydrolysis determined in the present study was similar to that reported by [@r003]. In the case of β-CN peptides, the C terminus was more hydrolyzed than the N-terminal ([Fig. 1](#f001){ref-type="fig"}). A large number of peptides were also found generated in this region from *Lactobacillus helveticus* ([@r039]), *Lactobacillus delbrueckii* subsp. *lactis* CRL 581 ([@r018]), *Lactobacillus bulgaricus* ([@r046]), *Lactobacillus lactis* subsp. *cremoris* ([@r035]), and *S. thermophilus* ([@r030]). On the other hand, the N terminus of β-CN was resistant to hydrolysis by *B. longum*, as previously reported by [@r003]. The C terminus of β-CN, which was determined to be a hydrophobic region in this study, is more accessible for hydrolysis by *B. longum* ([@r003]) and by the proteases of *S. thermophilus* ([@r002]; [@r030]) and *L. helveticus* ([@r039]).

![**Cleavage sites of peptide bonds on bovine β-, α~s1~-, and κ-casein hydrolyzed after fermentation with *Bifidobacterium longum* KACC9156.** The dot arrows cleaved peptide bonds in this study. The line arrow cleaved peptide bonds reported by [@r003].](kosfa-35-738-f001){#f001}

For α~s1~-CN, the hydrolysis pattern was also consistent with the results of [@r003], who reported that *B. longum* hydrolyzed the N-terminal region to a greater extent than the C-terminal region. In spite of the similar hydrolysis patterns, the observed cleavage pattern ([Fig. 1](#f001){ref-type="fig"}) was slightly different to the result obtained by [@r003] for *B. longum*, in which we observed relatively more cleavage sites on α~s1~-CN. The reason for the different cleavage patterns might be that the structure of α~s1~-CN was changed during fermentation in milk to make it more accessible for hydrolysis by *B. longum*. A similar result was reported by [@r002] and [@r040], who also found that the proteases PrtS and PrtH of *S. thermophilus* and *L. helveticus*, respectively, were more accessible at the N terminus than the C terminus.

In this study, regions found to be resistant to hydrolysis were also identified in the β-CN and α~s1~-CN sequences. This may be due to the presence of phosphoserine residues in these regions, which leads to high resistance to hydrolysis ([@r002]; [@r023]). In present work, five and eight phosphoserine residues were identified in the regions that were not hydrolyzed on β-CN and α~s1~-CN, respectively.

In the case of κ-CN, the cleavage site ([Fig. 1](#f001){ref-type="fig"}) only showed the generation of one peptide, whereas [@r003] found two peptides in this region. Furthermore, [@r048] reported that the glycomacropeptide (f106-169) region, composed of glycan chains, was difficult to hydrolyze because of the presence of hydrophilic amino acids and a negative charge, leading to increased electrostatic repulsion. However, in the present study, only one peptide, f150-151, of this casein was obtained. Fermentation with *B. longum* could induce a structural change due to weak bond of glycan chains on this glycomacropeptide region that would allow *B. longum* to access κ-CN for hydrolysis.

As the previously study by [@r003] who reported that no peptide detected from α~s2~-CN from 0.1% CN solution in 0.05 M sodium phosphate buffer (pH 7.0), none of the peptides identified were found in \<3 kDa fraction from fermentate. This observation could be explained by the results of [@r044], who found a protected region due to the formation of a tetrameric complex from CN that was more resistant to hydrolysis. [@r030] also suggested that accessibility of this region depends on its protein structure change.

Milk proteins play role precursors to release many peptides relating biological activity ([@r024]), i.e., ACE inhibitory peptide as this work.

Thirty two peptides relating ACE inhibitory obtained from casein have been reported in literature ([Table 3](#t003){ref-type="table"}). Out of 28 peptides generated from bovine casein during fermentation in present study, only 3 peptides from β-CN identified through MS/MS analysis (ESI-Q-TOF), YQEP-VLGPVRGPFPIIV, QEPVLGPVRGPFPIIV, GPVRGPFPIIV corresponded to ACE inhibitory bioactive peptides ([Table 3A](#t003){ref-type="table"}). These peptides were consistent with the previously studies reviewed by [@r047], [@r011] and [@r013], respectively. However no ACE inhibitory peptide released from other casein reported in previously study was present. These 3 peptides identified in this study were known the antihypertensive peptide in the literature. Thus, ACE inhibitory activity shown in [Table 1](#t001){ref-type="table"} might result from these peptides.

###### Antihypertensive and potential antihypertensive peptides generated by fermentation by *Bifidobacterium longum* KACC 91563 after 24 h at 37℃

  Sequence
  ------------------------------------------------------------
  A. Bioactive peptides clearly identified in the literature

^a^Peptides obtained from the fermentates in milk with *B. longum* in the present study.

Actually, peptides which have the high ACE inhibitory activity contain several amino acids (Trp, Phe, Tyr, or Pro) at the extremity of C-terminal and Ala, Val, IIe and Ser called aliphatic amino acids at the N-terminal ([@r022]). The three peptides, YQEPVLGPVRGPFPIIV, QEPVLGPVRGPFPIIV, GPVRGPFPIIV identified in present study contain these amino acids except for 4 amino acids, Gln, Glu, Leu and Gly. Thus, from these results, the peptides identified were reasonable to show the antihypertensive activity.

Other peptides as potential antihypertensive peptides which were included the fragment having ACE inhibitory activity were also identified in this study. These peptides were listed in [Table 3B](#t003){ref-type="table"} displaying 6 for β-CN and 9 for α~s1~-CN. Peptide, RELEELNVPGEIVE (f1-14) released from β-CN identified in present study contains LNVPGEIVE reviewed by [@r011] as ACE inhibitory peptide. Another peptide, YQEPVLGPVRGPFP (f193-206) from β-CN, contains also the ACE inhibitory peptide, YQEPVLGPVR ([@r036]). The others from β-CN, the fragment GPVRGPFPIIV reviewed by [@r013] as antihypertensive peptide was included in 4 peptides, EPVLGPVRGPFPIIV, PVLGPVRGPFPIIV, VLGPVRGPFPIIV, LGPVRGPFPIIV.

For peptides obtained from α~s1~-CN, the 9 peptide, APSFSDIPNPIGSENSEKTTMPLW (f176-199), SFSDIPNPIGSENSEKTTMPLW (f178-199), FSDIPNPIGSENSEKTTMPLW (f179-199), SDIPNPIGSENSEKTTMPLW (f180-199), DIPNPIGSENSEKTTMPLW (f181-199), IPNPIGSENSEKTTMPLW (f182-199), PIGSENS EKTTMPLW (f185-199), IGSENSEKTTMPLW (f186-199), SENSEKTTMPLW (f188-199) was released ([Table 3B](#t003){ref-type="table"}). These peptides contain the peptide TTMPLW (f154-199) which have reviewed that this peptide has a biological activity to inhibit ACE ([@r028]; [@r034]). The antihypertensive peptide, SDIPNPIGSENSEKTTMPLW (f180-199) occurring naturally in milk, was also reviewed by [@r020].

From our results, these 15 peptides obtained from β-CN and α~s1~-CN during fermentation with *B. longum* may be presented the antihypertensive activity ([Table 3B](#t003){ref-type="table"}) during digestion *in vivo*. [@r002] have reported that some peptides containing bioactive peptide fragment could be released during digestion. To verify whether these peptides show the ACE inhibitory activity as novel antihypertensive peptide after synthesis of these peptides, whether these peptides during digestion with gastro-intestinal enzyme i.e., pepsin, trypsin, chymotrypsin, pancreatin etc. will be short and generated as antihypertensive peptide reviewed in literature and also whether peptides generated during digestion will be novel antihypertensive peptide, the further study will need.

Conclusions {#s4}
===========

Antihypertensive activity was demonstrated in the low-molecular-weight fraction (\<3 kDa) obtained from the fermentate after milk fermentation with *B. longum*. This fraction was used to identify the CN-derived ACE inhibitory peptides. Using mass spectrometry analysis, three peptides showing antihypertensive activity and 15 peptides with potential antihypertensive activity were identified from CN. Thus, our results suggest that, given its capacity to generate antihypertensive peptides, *B. longum* KACC 91563 could be used as a starter culture with other lactic acid bacteria in the dairy industry and/or these peptides could be used in functional food manufacturing as antihypertensive agents, owing to their beneficial effects for human health.
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